A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
about
JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Myelofibrosis: an update on drug therapy in 2016.The role of the extracellular matrix in primary myelofibrosis.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.Developmental Therapeutics in Myeloproliferative Neoplasms.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
P2860
Q38684435-DAD417AB-28F1-4A5B-AD64-8BD033F0EE7EQ38691019-5AF8FCF8-23D3-4A3F-B605-7A24F8741017Q38989215-861C15B8-AE15-4404-A29D-38C107169947Q39117766-99EBB895-5101-440F-96FD-A2F1C3CF4C24Q47133172-3F87BB7F-0A4A-47BC-84E6-B53CF812EA96Q47581193-B25FDABB-0356-4BFF-8069-2AC943C2C0D5Q47784419-2149D08D-B3AC-431C-B7B0-C92EC19BB14AQ48008083-8F9F37F2-8DCD-4714-A066-69960529E56BQ48109284-DE209B54-A750-4B0E-990C-77618DD1A51D
P2860
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@ast
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@en
type
label
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@ast
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@en
prefLabel
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@ast
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@en
P2093
P2860
P356
P1433
P1476
A phase I, open-label, dose-es ...... in patients with myelofibrosis
@en
P2093
C Jamieson
M Wadleigh
P2860
P2888
P304
P356
10.1038/LEU.2016.215
P577
2016-08-01T00:00:00Z
P6179
1006146069